Replies to post #256762 on Biotech Values

[dewophile]

There’s a ton of room for improvement. You have to have low baseline HBSAg for starters in these trials and cures are going to be 20-30 percent (perhaps higher w very low baseline levels)
So enta drug could still find a role but obviously a long shot